Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovAliX has signed a multi-year drug research pact in the field of trisomy 21 with the Fondation Jérôme Lejeune
Subscribe to our email newsletter
Under the agreement, NovAliX is expected to use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the cystathionine-beta-synthase (CBS).
The Fondation Jerome Lejeune chief scientific officer Henri Blehaut said they look forward to progressing their research programs for treating trisomy 21 leveraging NovAliX expertise in structure-based drug design and capabilities in advanced lead generation methodologies.